I N D U S T R Y I N V E S T I G A T I O N
“ We are honoured to introduce MolecuLight’ s advanced real-time fluorescence imaging technology to Taiwan,” remarked Wei-Pin Hsieh, Chief Executive Officer of Healtdeva Company.
“ This innovation provides clinicians with a more efficient and accurate tool for assessing infections, opening up new diagnostic perspectives in the management of complex wounds and post-operative care. We firmly believe that this technology will have a profound impact on improving patient outcomes and reducing overall healthcare costs.”
This study underscores the growing recognition of MolecuLight’ s significant utility beyond chronic wound care and its increasing adoption in critical surgical applications. The company’ s advanced imaging system, with its unique ability to visualise bacterial presence in real time and guide targeted interventions, is gaining traction among surgeons looking to optimise outcomes and better manage post-operative complications in various surgical procedures, including the management of deep sternal wound infections( DSWI).
“ We wish to commend the researchers for their excellent work on this study,” said Anil Amlani, Chief Executive Officer of MolecuLight.“ These compelling results further validate the significant clinical and economic value of MolecuLight’ s technology, not only in chronic wound care but also in critical surgical applications. This study, along with our growing adoption in surgical settings, reflects the increasing recognition of our ability to provide critical, real-time information that empowers clinicians to make better decisions at the point of care, ultimately improving patient outcomes and reducing the burden of post-operative complications. We are proud to partner with Healtdeva Company to bring these benefits to patients in Taiwan.” �
www. intelligenthealth. tech 43